echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sialon Pharmaceutical's Milrinone Injection Obtained Approval for Supplemental Drug Application

    Sialon Pharmaceutical's Milrinone Injection Obtained Approval for Supplemental Drug Application

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 10, Sailong Pharmaceutical Group Co.
    , Ltd.
    announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co.
    , Ltd.
    , has recently obtained the “Approval for Supplementary Drug Application for Milrinone Injection” approved and issued by the State Drug Administration.
    Notice"
    .

    It is reported that the main indication of milrinone injection is for short-term intravenous treatment of patients with acute decompensated heart failure
    .


    It is worth mentioning that Theron Pharmaceuticals has changed the prescription process and storage conditions in the application content


    Sialon Milrinone injection has passed the quality and efficacy consistency evaluation of generic drugs, and the new 10ml:10mg specification is conducive to optimizing the company's product structure, better meeting clinical drug needs, and further enhancing the product's market.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.